The companies in the Latin America (LATAM) cord blood banking services are operating amidst highly competitive environment. Considering their presence in large numbers, the LATAM cord blood banking services market exhibit a highly fragmented vendor landscape, finds Transparency Market Research (TMR) in a new study. “While there is distinction between private and public cord blood banking services, it is expected to have little impact on easing the competitive trends,” said a lead TMR analyst.
Private cord blood banks offer services to individual families in return of annual payment, while public banks cater to the general population. There is little difference in storage technologies between private and public banks. However, the method of collecting samples varies as private banks give collection kits to patients who in turn give them to obstetricians. Among the companies that succeeded leaving a mark, Banco de Cordon Umbilical (BCU), America Cell Biobank, Inc., Redcord S.A., and CrioCenter have established a strong presence in the LATAM cord blood banking services market.
This 91 page report gives readers a comprehensive overview of the LATAM Cord Blood Banking Services Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/latam-cord-blood-banking-services-market.html
TMR forecasts, the market to exhibit a CAGR of 9.4% between 2015 and 2023. At this pace, the LATAM cord blood banking services market will reach US$445.4 mn by the end of 2023, from its valuation of US$196.9 mn in 2014. Based on storage type, the rising incidence of genetic diseases and better apprehension of such disorders considering the availability of high-end diagnostic techniques has rendered dominance to the private cord blood banking services segment. Country-wise, Argentina, Brazil, Mexico, and Columbia are expected to offer the most lucrative opportunities for the players operating in the Latin America cord blood banking services market.
Favorable Government Initiatives to Support Market’s Growth
In the last few years, the world witnessed a surge in cord blood banking practice, thanks to recent advancements in stem cell therapy research. Also rapidly evolving technology and infrastructure in most economies is paving way for the market’s growth in Latin America. It is important to note here that a majority of cord blood banks in Latin America are buoyed by government funding. However, with the foray of several private players, the dynamics of the LATAM cord blood banking services market is altering fast. Considering pace of gains witnessed by the market players, expert foresee the entry of several companies in the coming years.
A majority of the established players in the Latin America cord blood banking services market also have established their presence in the field of engineering, stem cell development, and non-invasive prenatal tests. Furthermore, countries across Latin America are focusing on mitigating drawbacks in public and private cord blood banking by implementing hybrid models. Spurred by these factors the LATAM cord blood banking services market is expected to report strong growth in the forecast period.
A considerable number of companies operating in the LATAM market are thus involved in storing the cord blood samples in two portions. While one portion is stored for the child or solely its family members, the other portion is kept available as public donation. Considering the rising incidence of chronic ailments and increase stem cell researches, the demand for cord blood kept for public donation is likely to rise in the coming years. This will give impetus to the market in the coming years.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving LATAM cord blood banking services market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8413
Stringent Regulation Compliance May Restrict Market’s Growth
On the down side, public and private cord blood banks require accreditation and regulation compliance from authorities as they apprehend life risk, if the industry is left inadequately regulated. Any discrepancy at any stage could adversely impact clinical product supplies. Stringent regulations implemented to monitor the activities of cord blood banks could have an adverse impact on the market. Nevertheless, rising research spending and favorable government initiatives adopted to promote public healthcare will aid in market’s expansion in the coming years.
This review is based on a TMR report, titled “Cord Blood Banking Services Market (Storage – Private Cord Blood Banking Services and Public Cord Blood Banking Services) – LATAM Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”
The global breast pumps market being highly consolidated, existing players are threatened to lose their market share to new entrants. In 2013, Medela, AG, Royal Philips Electronics N.V., and Ameda AG emerged dominant in the market, cumulatively accounting for a share of 79%, states Transparency Market Research (TMR) in a new study. Besides the established enterprises, many small-scale suppliers of breast pumps operate in the market through a crude network of distribution. Hence a significantly large number of players operate in the market, with only a few accounting for its lion’s share. This is indicative of the high competition prevailing in the market.
According to TMR, the global breast pumps market is forecast to exhibit a CAGR of 8.6% between 2014 and 2022. At this pace, the market is projected to reach US$2.6 bn by the end of 2022, from a valuation of US$1.2 bn in 2013. The TMR report has studied the global breast pumps market from two perspectives, which are product and geography. In terms of products the single electric pump segment held dominance in 2013 with a valuation of US$472.9 mn. Regionally, North America emerged dominant with a share of 60.2% in 2013.
This 104 page report gives readers a comprehensive overview of the breast pumps market. Browse through 16 data tables and 31 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/breast-pumps-market.html
Favorable Reimbursement Policies to Encourage Uptake of Breast Pumps
The rising population has a direct impact on the global breast pumps market. The increasing birth-rate often corresponds to the increasing uptake of breast pumps. Because the developing regions demonstrate a higher birth rate, opportunities for the market are considered higher in there. In addition, the rising disposable income of consumers will positively influence the willingness to spend on advanced medical devices thus accentuating the uptake of breast pumps.
The favorable reimbursement policies are further supporting growth of the global breast pumps market. The pace of gains for the market is projected to accelerate as developed nations such as the U.S. introduce more benefits such as the Affordable Care Act of 2010. The provision mandated every insurance company in the country to cover devices and services that support breast feeding. On the downside, the law did not include specific names of brands that could be purchased through insurance. This lack of specificity could end up in variations in benefits offered under any health plan.
Nevertheless, governments are trying to implement more comprehensive laws to promote health and wellness of both mother and child. Besides this, the growing awareness and higher availability of advanced medical devices is likely to augment the market’s growth during the course of the forecast period.
High Price of Breast Pumps Limits their Uptake across Developing Nations
Despite the string of benefits it provides, the pricing of the medical device is a major factor limiting the widespread uptake of breast pumps. This is especially true in case of developing nations where the purchasing power of consumers is comparatively low. The high prices of breast pumps that are not technologically advanced and complex to use mostly leads to hesitance among users to spend on the product. The risk of contamination often associated with used pumps also hampers the growth of the market. Contamination generally occurs when mothers purchase used pumps that might contain infections that could be passed on infants.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving breast pumps market during 2014 – 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=687
Smaller Players Looking to Capitalize on Unmet Medical Needs across Emerging Nations
As key market players have successfully registered dominance across developed economies, the smaller companies are looking to tap into the unmet medical needs across emerging nations. Developing economies in Asia Pacific and Latin America hold immense opportunities for the growth of these players. Besides this, companies are also focusing on developing innovative breast pumps to gain dominance in the global market.
This review is based on information published by TMR in a report, titled “Breast Pumps Market – Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 – 2022.”
The global molecular diagnostics market features a highly consolidated vendor landscape, with the top three players, namely F. Hoffmann-La Roche Ltd., Abbott Laboratories, and Danaher Corporation, representing over 54% of the overall market. The dominance of these players can be attributed to their broad product portfolio, finds Transparency Market Research (TMR) in a study. “Several players are going the mergers and acquisitions routes to stay ahead of the curve. For instance, Danaher acquired Cepheid in 2016 which is poised to the operational efficiencies and expand their diagnostic units,” says TMR’s lead analyst.
Well-established Healthcare Infrastructure behind North America’s Dominance
The valuation of the global US$7.10 bn in 2016 and is estimated to reach US$18.98 bn by 2024, exhibiting a CAGR of 11.6% from 2017 to 2025. On the basis of end user, diagnostic laboratories will continue to dominate the market until 2025, accounting for 38.5% of the overall market value. The availability of well-equipped and sophisticated instruments in diagnostic labs make them a preferred choice for diagnosis. The segment is expected to register a strong growth during the forecast period.
This 164 page report gives readers a comprehensive overview of the molecular diagnostics market. Browse through 30 data tables and 76 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/molecular-diagnostics-industry.html
Geographically, North America will continue to be at the forefront of growth until 2025. Changing demographics, growing incidence of cancer, and well-established healthcare infrastructure are contributing to the dominance of the region. Asia Pacific is anticipated to post a noteworthy CAGR of 12.2% during the same period, owing to the improving healthcare infrastructure and the increasing acceptance of technologically advanced products.
Growing Incidence of Cancer and Infectious Diseases Boosts Demand for Molecular Diagnostics
Governments worldwide are allocating significant budgets to the healthcare sector, which in turn influences diagnostics healthcare. For instance, in 2015, the overall share of the U.S. economy devoted to health care spending was 17.8%. Therefore, the increasing government funding is augmenting the global molecular diagnostics market. Moreover, the growing inclination towards personalized medicines is translating into the greater uptake of molecular diagnostics worldwide.
Another important factor stoking the global market is the rising prevalence of infectious diseases and cancer. “Expanding base of patients suffering from cancer is creating a soaring need for efficient and target-specific medicines, which in turn is triggering the demand for personalized medicines,” says a TMR analyst. The trailblazing researches in the field of biomarkers are also working in favor of the market. Furthermore, continuous advancements in technology, growing global geriatric population, and improving consumer expending power on healthcare are providing a fillip to the market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving molecular diagnostics market during 2017 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783
Complex Regulatory Framework Inhibits Growth Prospects
The complex regulatory scenario is leading to delays in the introduction of new treatments and also makes them expensive, which in turn is negatively impacting the growth of the global molecular diagnostics market. “Insurance companies are refraining from reimbursing molecular diagnostic tests due to lack of appropriate coding system,” says an analyst. This is leading to unfavorable reimbursement scenario, thereby negatively impacting the growth of the market. Moreover, the lack of awareness and ambiguities related to molecular diagnostics are adversely affecting the growth of the market.
The above data has been derived from a report by TMR, titled “Molecular Diagnostics Market (Technology – PCR and Real-Time PCR, Hybridization, Microarray, Transcription-mediated Amplification, and Next-Generation Sequencing; Application – Infectious Diseases, Oncology, Blood Screening, Microbiology, Genetic Testing, and Women’s Health; End User: Hospitals, Diagnostic Laboratories, Blood Banks, Academics, and Research) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.”
In-vitro Colorectal Cancer Screening Tests Market: Impact of Key Factors Influencing the Parent Industry
The top three players in the global in-vitro colorectal cancer screening tests market are Sysmex Corporation, Quest Diagnostics, Inc., and Beckman Coulter, Inc. The collective share of these players, in terms of revenue, stood at 68.3% in 2014. Transparency Market Research observes that only a few players dominate the global market, as sustainability in the market demands high investment in research and development. This factor has dissuaded new entrants from entering the market to a large extent. “Product innovation is expected to be the key growth strategy of the players in the global market,” states the lead author of this research report.
Europe to Progress at a Noteworthy CAGR of 8.3% 2015-2023
According to the research report, the global in-vitro colorectal cancer screening tests market is expected to be worth US$980.6 mn by the end of 2023 from US$602.3 mn by the end of 2016. The global market is anticipated to expand at a CAGR of 7.5% between 2015 and 2023. Europe is expected to be a lucrative market for the in-vitro colorectal cancer screening testing as the region is witnessing a high incidence of colorectal cancer amongst the geriatrics. The regional market is expected to progress at a CAGR of 8.3% during the forecast period. The blood biomarkers tests are expected to register a significant CAGR of 9.9% due to the development of technologies associated with genomics and proteomics.
This 95 page report gives readers a comprehensive overview of the in-vitro colorectal cancer screening testing market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/in-vitro-colorectal-cancer-screening-tests-market.html
High Incidence of Colorectal Cancer amongst Geriatrics Encourages Uptake of Screening Tests
The primary factor driving the growth of the global in-vitro colorectal cancer screening test market is the increasing preference for the non-invasive diagnostics. The huge pool of geriatrics, who are also fueling the growth of this market, are opting for the non-invasive measure as they reduce recovery time and offer ease of operation to the medical professional. These methods also eliminate the hassle of dietary restrictions and are also known to be exceptionally effective.
The market is also being favored by growing number of people with a history of inflammatory bowel disease such as Crohn’s disease, which has a tendency to result in colorectal cancer. Furthermore, rising number patients suffering from infections to the gastrointestinal system, respiratory tract, and ulcerative colitis has also created a significant surge in the number of in-vitro colorectal cancer screening tests in recent past. The growing number of diabetics are also projected to contribute toward the rise of the global market as they remain susceptible to such diseases.
Substantial advancements in technology, which has rendered a positive effect on the life expectancy of patients, have played a vital role in the growth of this market. The growing awareness about the disease and increased spending by the governments to spread awareness about it has also made a significant contribution to the global market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving in-vitro colorectal cancer screening testing market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3698
Tough Compliance Norms Deter Global Market
The rigmarole of obtaining approvals for in-vitro colorectal cancer screening tests has been the Herculean task for several companies operating in the global market. The companies are expected to find it even more difficult as the regulatory norms are getting even tougher to comply with. The U.S. FDA and EMA have made their protocol severely strict in recent years for both existing players as well as new entrants. Thus, this is expected to restrain the global market to a significant extent in the near future. The poor reimbursement schemes, especially in the developing countries are also hampering the overall market.
The review is based on the research report by Transparency Market Research, titled “In-vitro Colorectal Cancer Screening Tests Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015-2023.”
With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production of these biotherapeutics. From 2006 to 2011 an average of 15 novel recombinant protein therapeutics and in 2014, 11 novel recombinant protein therapeutics have been approved by US FDA. About forty-seven monoclonal antibody products have been approved in the U.S., Europe and other global markets, of which over 60% were produced in mammalian cell culture. Moreover, the rise in the geriatric population coupled with prevalence of diseases is one of the major factors driving the demand for cell line development for biotherapeutics. The increasing demand for monoclonal antibodies across the globe boosts the market growth. In addition, the increasing number of initiatives taken by the government of various countries by funding the life science research and development is expected to propel this market in coming years.
This 104 page report gives readers a comprehensive overview of the Biotherapeutics Cell Line Development Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html
The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further sub-segmented by method into manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014. Geographically, the market has been studied and estimated for five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes market attractiveness analysis, by geography, to provide a thorough analysis of the overall competitive scenario in the global biotherapeutics cell line development market. The market overview section of the report also includes the qualitative and quantitative analysis of the competitive landscape.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biotherapeutics Cell Line Development Market during 2015 – 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272
Market share analysis for FACS market is also provided in the market overview section of the report for 2014 in terms of value (%). The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the biotherapeutics cell line development market across the world. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Becton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.).